Literature DB >> 26459813

Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010.

Chaturia Rouse1, Haley Gittleman1, Quinn T Ostrom1, Carol Kruchko1, Jill S Barnholtz-Sloan1.   

Abstract

BACKGROUND: Years of potential life lost (YPLL) complement incidence and survival rates by measuring how much a patient's life is likely to be shortened by his or her cancer. In this study, we examine the impact of death due to brain and other central nervous system (CNS) tumors compared to other common cancers in adults by investigating the YPLL of adults in the United States.
METHODS: Mortality and life table data were obtained from the Centers for Disease Control and Prevention's National Center for Health Statistics Vital Statistics Data for 2010. The study population included individuals aged 20 years or older at death who died from one of the selected cancers. YPLL was calculated by taking an individual's age at death and finding the corresponding expected remaining years of life using life table data.
RESULTS: The cancers with the greatest mean YPLL were other malignant CNS tumors (20.65), malignant brain tumors (19.93), and pancreatic cancer (15.13) for males and malignant brain tumors (20.31), breast cancer (18.78), and other malignant CNS tumors (18.36) for females. For both sexes, non-Hispanic whites had the lowest YPLL, followed by non-Hispanic blacks, and Hispanics.
CONCLUSION: Malignant brain and other CNS tumors have the greatest mean YPLL, thereby reflecting their short survival time post diagnosis. These findings will hopefully motivate more research into mitigating the impact of these debilitating tumors.
© The Author(s) 2015. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  CBTRUS; NCHS; central nervous system tumors; years of potential life lost

Mesh:

Year:  2015        PMID: 26459813      PMCID: PMC4677421          DOI: 10.1093/neuonc/nov249

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  12 in total

1.  Years of potential life lost (YPLL)--what does it measure?

Authors:  J W Gardner; J S Sanborn
Journal:  Epidemiology       Date:  1990-07       Impact factor: 4.822

2.  Measuring the societal burden of cancer: the cost of lost productivity due to premature cancer-related mortality in Europe.

Authors:  Paul Hanly; Isabelle Soerjomataram; Linda Sharp
Journal:  Int J Cancer       Date:  2014-09-04       Impact factor: 7.396

3.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter Liao; Chaturia Rouse; Yanwen Chen; Jacqueline Dowling; Yingli Wolinsky; Carol Kruchko; Jill Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2014-10       Impact factor: 12.300

4.  Hispanic older adult mortality in the United States: new estimates and an assessment of factors shaping the Hispanic paradox.

Authors:  Joseph T Lariscy; Robert A Hummer; Mark D Hayward
Journal:  Demography       Date:  2015-02

5.  Years of potential life lost caused by prostate cancer deaths in the United States-Projection from 2004 through 2050.

Authors:  Chunyu Li; Donatus U Ekwueme
Journal:  Cancer Epidemiol       Date:  2010-05-26       Impact factor: 2.984

6.  Expected years of life lost for six potentially preventable cancers in the United States.

Authors:  Pang-Hsiang Liu; Jung-Der Wang; Nancy L Keating
Journal:  Prev Med       Date:  2013-02-19       Impact factor: 4.018

7.  Years of potential life lost and productivity costs because of cancer mortality and for specific cancer sites where human papillomavirus may be a risk factor for carcinogenesis-United States, 2003.

Authors:  Donatus U Ekwueme; Harrell W Chesson; Kevin B Zhang; Appathurai Balamurugan
Journal:  Cancer       Date:  2008-11-15       Impact factor: 6.860

8.  Deaths: leading causes for 2010.

Authors:  Melonie Heron
Journal:  Natl Vital Stat Rep       Date:  2013-12-20

9.  Years of life lost (YLL) from cancer is an important measure of population burden--and should be considered when allocating research funds.

Authors:  N G Burnet; S J Jefferies; R J Benson; D P Hunt; F P Treasure
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

10.  Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010.

Authors:  Haley R Gittleman; Quinn T Ostrom; Chaturia D Rouse; Jacqueline A Dowling; Peter M de Blank; Carol A Kruchko; J Bradley Elder; Steven S Rosenfeld; Warren R Selman; Andrew E Sloan; Jill S Barnholtz-Sloan
Journal:  Cancer       Date:  2014-08-25       Impact factor: 6.860

View more
  29 in total

1.  Near Infrared Fluorescent Nanoplatform for Targeted Intraoperative Resection and Chemotherapeutic Treatment of Glioblastoma.

Authors:  Derek Reichel; Bien Sagong; James Teh; Yi Zhang; Shawn Wagner; Hongqiang Wang; Leland W K Chung; Pramod Butte; Keith L Black; John S Yu; J Manuel Perez
Journal:  ACS Nano       Date:  2020-06-23       Impact factor: 15.881

Review 2.  The development of dendritic cell vaccine-based immunotherapies for glioblastoma.

Authors:  David A Reardon; Duane A Mitchell
Journal:  Semin Immunopathol       Date:  2017-01-30       Impact factor: 9.623

3.  Do race and age vary in non-malignant central nervous system tumor incidences in the United States?

Authors:  Haley Gittleman; David J Cote; Quinn T Ostrom; Carol Kruchko; Timothy R Smith; Elizabeth B Claus; Jill S Barnholtz-Sloan
Journal:  J Neurooncol       Date:  2017-06-30       Impact factor: 4.130

4.  Developing Implantable Scaffolds to Enhance Neural Stem Cell Therapy for Post-Operative Glioblastoma.

Authors:  Kevin T Sheets; Matthew G Ewend; Mahsa Mohiti-Asli; Stephen A Tuin; Elizabeth G Loboa; Karen S Aboody; Shawn D Hingtgen
Journal:  Mol Ther       Date:  2020-02-13       Impact factor: 11.454

Review 5.  Advances in the molecular genetics of gliomas - implications for classification and therapy.

Authors:  Guido Reifenberger; Hans-Georg Wirsching; Christiane B Knobbe-Thomsen; Michael Weller
Journal:  Nat Rev Clin Oncol       Date:  2016-12-29       Impact factor: 66.675

6.  Recurrent Thromboembolic Events after Ischemic Stroke in Patients with Primary Brain Tumors.

Authors:  Neal S Parikh; Jaclyn E Burch; Hooman Kamel; Lisa M DeAngelis; Babak B Navi
Journal:  J Stroke Cerebrovasc Dis       Date:  2017-06-21       Impact factor: 2.136

7.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016.

Authors:  Quinn T Ostrom; Gino Cioffi; Haley Gittleman; Nirav Patil; Kristin Waite; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2019-11-01       Impact factor: 12.300

8.  BDNF, COMT, and DRD2 polymorphisms and ability to return to work in adult patients with low- and high-grade glioma.

Authors:  David B Altshuler; Lin Wang; Lili Zhao; Zachary Miklja; Joey Linzey; Amanda Brezzell; Sofia Kakaizada; Saritha Krishna; Daniel A Orringer; Emily M Briceño; Nicolette Gabel; Shawn L Hervey-Jumper
Journal:  Neurooncol Pract       Date:  2019-04-10

9.  Meta-Analyses of Splicing and Expression Quantitative Trait Loci Identified Susceptibility Genes of Glioma.

Authors:  C Pawan K Patro; Darryl Nousome; Rose K Lai
Journal:  Front Genet       Date:  2021-04-15       Impact factor: 4.772

10.  Receptor-Interacting Protein 140 Enhanced Temozolomide-Induced Cellular Apoptosis Through Regulation of E2F1 in Human Glioma Cell Lines.

Authors:  Hong-Chieh Tsai; Kuo-Chen Wei; Pin-Yuan Chen; Chiung-Yin Huang; Ko-Ting Chen; Ya-Jui Lin; Hsiao-Wei Cheng; Chun-Hao Huang; Hsiang-Tsui Wang
Journal:  Neuromolecular Med       Date:  2021-06-01       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.